US FDA says Ranbaxy plant falsified data
WASHINGTON |
WASHINGTON Feb 25 (Reuters) - A plant owned by Indian drugmaker Ranbaxy Laboratories (RANB.BO) falsified data and test results in approved and pending drug applications, U.S. regulators said on Wednesday.
The Food and Drug Administration said it halted review of drug applications from Ranbaxy's Paonta Sahib plant in India. (Reporting by Lisa Richwine, editing by Lisa Von Ahn)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters